GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Life Sciences Ltd (BOM:543322) » Definitions » Beneish M-Score

Glenmark Life Sciences (BOM:543322) Beneish M-Score : -2.16 (As of May. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Glenmark Life Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.16 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Glenmark Life Sciences's Beneish M-Score or its related term are showing as below:

BOM:543322' s Beneish M-Score Range Over the Past 10 Years
Min: -2.44   Med: -2.28   Max: -2.16
Current: -2.16

During the past 6 years, the highest Beneish M-Score of Glenmark Life Sciences was -2.16. The lowest was -2.44. And the median was -2.28.


Glenmark Life Sciences Beneish M-Score Historical Data

The historical data trend for Glenmark Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Life Sciences Beneish M-Score Chart

Glenmark Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
Get a 7-Day Free Trial - -2.44 -2.36 -2.19 -2.16

Glenmark Life Sciences Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 - - - -2.16

Competitive Comparison of Glenmark Life Sciences's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Life Sciences's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Glenmark Life Sciences's Beneish M-Score falls into.



Glenmark Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Glenmark Life Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8551+0.528 * 0.9459+0.404 * 1.3143+0.892 * 1.0564+0.115 * 0.8632
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.020128-0.327 * 0.8244
=-2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ₹7,654 Mil.
Revenue was ₹22,832 Mil.
Gross Profit was ₹12,812 Mil.
Total Current Assets was ₹19,160 Mil.
Total Assets was ₹28,504 Mil.
Property, Plant and Equipment(Net PPE) was ₹8,962 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹535 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹4,388 Mil.
Long-Term Debt & Capital Lease Obligation was ₹148 Mil.
Net Income was ₹4,709 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹4,135 Mil.
Total Receivables was ₹8,473 Mil.
Revenue was ₹21,612 Mil.
Gross Profit was ₹11,471 Mil.
Total Current Assets was ₹18,503 Mil.
Total Assets was ₹27,021 Mil.
Property, Plant and Equipment(Net PPE) was ₹8,242 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹421 Mil.
Selling, General, & Admin. Expense(SGA) was ₹338 Mil.
Total Current Liabilities was ₹5,044 Mil.
Long-Term Debt & Capital Lease Obligation was ₹171 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7654.32 / 22832.14) / (8473.36 / 21612.2)
=0.335243 / 0.392064
=0.8551

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(11471.32 / 21612.2) / (12812.04 / 22832.14)
=0.53078 / 0.561141
=0.9459

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19159.99 + 8961.97) / 28504.12) / (1 - (18503.39 + 8242.44) / 27021.47)
=0.013407 / 0.010201
=1.3143

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=22832.14 / 21612.2
=1.0564

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(420.94 / (420.94 + 8242.44)) / (534.52 / (534.52 + 8961.97))
=0.048588 / 0.056286
=0.8632

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 22832.14) / (337.68 / 21612.2)
=0 / 0.015625
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((147.61 + 4387.73) / 28504.12) / ((170.92 + 5044.14) / 27021.47)
=0.159112 / 0.192997
=0.8244

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(4708.88 - 0 - 4135.15) / 28504.12
=0.020128

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Glenmark Life Sciences has a M-score of -2.16 suggests that the company is unlikely to be a manipulator.


Glenmark Life Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Glenmark Life Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Life Sciences (BOM:543322) Business Description

Traded in Other Exchanges
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark Life Sciences (BOM:543322) Headlines

No Headlines